Data from the Phase I study for VLA1553, Valneva's chikungunya vaccine candidate, showed it diminished clinical illness risk with a single vaccination and also induced high-titer neutralizing antibodies, according to research published in the journal The Lancet. Results from VLA1553's midstage trial were also successful, and the company is now preparing to launch its late-stage trial in the US later this year.
Novavax has chosen AGC Biologics to help manufacture the company's experimental COVID-19 vaccine, with AGC to produce an add-on component of the vaccine.
Chinook Therapeutics has agreed to merge with Aduro Biotech and will focus on taking a former AbbVie renal drug through Phase III with $180 million from the deal. Aduro brings to the table the anti-APRIL antibody BION-1301, a drug being tested as a treatment for IgA nephropathy.
Moderna could begin Phase III of its COVID-19 vaccine trial, enrolling 30,000 people, in July, possibly around the same time as a vaccine from AstraZeneca and Oxford University enters late-stage testing. NIAID Director Anthony Fauci said that study will be closely aligned with Moderna's study.
Scientists in China used CRISPR-Cas9 gene editing to create a mouse that can become infected with SARS-CoV-2, and mice that were infected nasally had viral RNA in their lungs, trachea and brain. Mice infected through the stomach developed gastrointestinal illness, but the infectious dose was 10 times as high as the nasal dose required to cause an infection.
Two House panel leaders sent a letter to HHS Secretary Alex Azar requesting details on government contracts with drug firms involving development of COVID-19 vaccines, noting the federal contracts published online don't include information such as allocation of patent rights. Reps. James Clyburn, D-S.C., and Carolyn Maloney, D-N.Y., said they want to know whether the contracts include provisions ensuring the affordability of any federally approved vaccines or therapeutics.
Gilead Sciences announced that it's evaluating other ways it can use remdesivir for COVID-19 at an earlier stage of the disease, particularly through alternate formulations, such as one that's inhalable and a subcutaneous injection formulation.
European regulators have given CE-IVD mark approval to MeMed for its MeMed Key platform and MeMed BV diagnostic test that can differentiate viral and bacterial infections.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sodium-glucose cotransporter 2 inhibitor canagliflozin for treating diabetic kidney disease. It is set to be the first agent to slow the progression of diabetic kidney disease to be approved in Europe in almost 20 years.
Terumo has signed a long-term distribution deal with Fibralign to distribute and market the BioBridge collagen matrix in Japan. BioBridge is a surgical mesh that is used to prevent and treat secondary lymphedema.